Abstract
Background: Genome-wide association studies (GWAS) of Alzheimer’s disease (AD) have identified several risk loci, but many remain unknown. Cerebrospinal fluid (CSF) biomarkers may aid in gene discovery and we previously demonstrated that six CSF biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and neurogranin) cluster into five principal components (PC), each representing statistically independent biological processes. Here, we aimed to (1) identify common genetic variants associated with these CSF profiles, (2) assess the role of associated variants in AD pathophysiology, and (3) explore potential sex differences. Methods: We performed GWAS for each of the five biomarker PCs in two multi-center studies (EMIF-AD and ADNI). In total, 973 participants (n = 205 controls, n = 546 mild cognitive impairment, n = 222 AD) were analyzed for 7,433,949 common SNPs and 19,511 protein-coding genes. Structural equation models tested whether biomarker PCs mediate genetic risk effects on AD, and stratified and interaction models probed for sex-specific effects. Results: Five loci showed genome-wide significant association with CSF profiles, two were novel (rs145791381 [inflammation] and GRIN2D [synaptic functioning]) and three were previously described (APOE, TMEM106B, and CHI3L1). Follow-up analyses of the two novel signals in independent datasets only supported the GRIN2D locus, which contains several functionally interesting candidate genes. Mediation tests indicated that variants in APOE are associated with AD status via processes related to amyloid and tau pathology, while markers in TMEM106B and CHI3L1 are associated with AD only via neuronal injury/inflammation. Additionally, seven loci showed sex-specific associations with AD biomarkers. Conclusions: These results suggest that pathway and sex-specific analyses can improve our understanding of AD genetics and may contribute to precision medicine.
| Original language | English |
|---|---|
| Article number | 79 |
| Journal | Genome Medicine |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 12.2023 |
Funding
| Funders | Funder number |
|---|---|
| Departments of Neurology and Psychiatry at Washington University School of Medicine | |
| Mayo Clinic Brain Bank | |
| EU IMI | |
| Familjen Erling-Perssons Stiftelse | |
| Rush University | |
| CurePSP | |
| Hope Center for Neurological Disorders | |
| EPAD | |
| Anonymous foundation | |
| New York Stem Cell Foundation | |
| National Center for Geriatrics and Gerontology | |
| European Union’s HorizonEurope Research and Innovation Programme | |
| Chan Zuckerberg Initiative | |
| National Institute of Biomedical Imaging and Bioengineering | |
| Arizona Biomedical Research Commission | |
| National Institute for Health and Care Research | |
| Fonds Wetenschappelijk Onderzoek | |
| Janssen Medical Ltd | |
| Lifebrain EU Horizon 2020 | |
| UCLH Biomedical Research Centre | |
| Department of Health of the Basque Government | |
| Akrivia Health Ltd | |
| University of Florida | |
| Icahn School of Medicine at Mount Sinai | |
| Olav Thon Stiftelsen | |
| Mayo and Michael J Fox foundations | |
| Koichi Iijima | |
| Columbia University | |
| Cure Alzheimer's Fund | |
| Alzheimer's Disease Neuroimaging Initiative | |
| Universiteit Antwerpen | |
| European Research Council | |
| DOD ADNI | |
| Michael J. Fox Foundation for Parkinson's Research | |
| Arizona Department of Health Services | |
| AD Strategic Fund | |
| National Institute on Aging | |
| AstraZeneca GmbH | |
| Neurogenomics and Informatics Center | |
| Horizon 2020 Framework Programme | 666992, 732592 |
| National Institutes of Health | U01AG006786, U01AG058922, P30AG19610, RF1AG058501, U01AG61356, R01AG044546, U24AG061340, P30AG10161, R01 AG032990, U24NS072026, U01AG046139, R01NS080820, R01AG025711, R01AG036836, P30AG72975, R01AG017216, U01AG006576, RF1AG057440, U01AG046170, R01AG018023, RF1AG053303, R01AG003949, P50 AG016574, U01AG46152, P01AG003991, U01 AG024904, R01AG17917, R01AG15819 |
| H2020 Marie Skłodowska-Curie Actions | 860197 |
| TEMPO | 101039672 |
| European Commission within the fifth framework program | 37670, QLRT-2001–2455 |
| Alzheimer’s Association | -21–831,376-C, -21–831,377-C, ZEN-22–848,604, -21–831,381-C |
| Vetenskapsrådet | 101,053,962, 2018–02532, 681,712 |
| Institute of Family Medicine | 101057529 |
| European Commission | 101057529, 115736 |
| Alzheimer's Drug Discovery Foundation | 201,809–2016862 |
| Deutsche Forschungsgemeinschaft | 2287/6–1, 2654/2–1, LI 2654/4–1 |
| Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden | 2022-0270 |
| U.S. Department of Defense | W81XWH-12–2-0012, LI- W81XWH2010849 |
| UK Dementia Research Institute | UKDRI-1003 |
| Innovative Medicines Initiative | 115372 |
| Stiftung Synapsis - Alzheimer Forschung Schweiz AFS | 2017-PI01 |
| Swedish State Support for Clinical Research | -71320 |
| Stichting voor Alzheimer Onderzoek | 15,005, 11,020, 13,007 |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 320030_141179 |
| EU Joint Programme – Neurodegenerative Disease Research | JPND2021-00694 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Medical Genetics
DFG Research Classification Scheme
- 2.23-06 Molecular and Cellular Neurology and Neuropathology
Fingerprint
Dive into the research topics of 'Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver